zadnja posodobitev :
19/11/2024
raziskovalne skupine - Quality Evaluation Team, Samsung Bioepis Co   pdf  
Japonska
farmacevtski laboratorij
Quality Evaluation Team, Samsung Bioepis Co
Incheon
Viri   Viri   (4)  
1
In‑Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M, Jeong H, Yun J, Kim J, Kim S, Lee Y, Park S-J. (sujin8171.park@samsung.com)
Drugs R D - 2023 - ;23,4:363 - 375
2
3
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Yun J, Kim J, Chung J, Hwang S-J, Park S-J. (sujin8171.park@samsung.com)
Adv Ther - 2019 -
4
Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D, Yun J, Hwang S-J, Park SJ. (sujin8171.park@samsung.com)
Adv Ther - 2019 - 36:442–450

Seznami   molekule študiral   (4)  
Zdravilo za zaviranje imunske odzivnosti Brizgalka Adalimumab
rak drog Brizgalka Bevacizumab
Različen Brizgalka Eculizumab
rak drog Brizgalka Trastuzumab

  Mentions Légales